Altibbi Partners with Haleon to Promote Oral Health in Saudi Arabia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Should l Buy HLN?
Source: Newsfilter
- Partnership Formation: Altibbi, the leading digital health platform in the Arab world, partnered with Haleon to enhance oral health awareness through the Healthy Saudi Smile campaign in Saudi Arabia.
- Educational Initiative: The campaign focuses on preventive care and oral health education, connecting users with certified doctors for instant consultations.
- Digital Access: Altibbi enabled Haleon to provide reliable Arabic-language oral health advice, significantly increasing user engagement and facilitating health actions.
- Future Expansion: Altibbi plans to expand similar collaborations with health brands, offering integrated solutions that connect education, access, and action to improve everyday health outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HLN
Wall Street analysts forecast HLN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.160
Low
13.44
Averages
13.44
High
13.44
Current: 11.160
Low
13.44
Averages
13.44
High
13.44
About HLN
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Solution for Sensitive Teeth: Sensodyne's Clinical Repair toothpaste starts repairing sensitive areas within 60 seconds and provides significant relief after three days of twice-daily brushing, addressing the needs of 85% of sensitive teeth sufferers seeking root cause solutions, thereby enhancing the brand's competitive position in the market.
- Innovative Repair Technology: The toothpaste features a scientifically-backed formula that activates during brushing to form a protective layer that strengthens with each use, offering more robust protection than two leading competitors, marking a technological advancement in sensitivity repair.
- Perfect for Daily Care: Clinical Repair is available in two options, Whiten & Shine and Fresh Clean, designed to meet consumer demands for sensitivity relief and cleaning benefits, thereby enhancing the overall daily oral care experience for users.
- Pricing and Availability: The product is now available at major retailers like Amazon, Walmart, and Target, with an MSRP of $8.99, and is expected to rapidly expand nationwide, further driving sales growth.
See More
- Brand Collaboration: TUMS partners with viral creator Airrack for a playful marketing campaign featuring trick shots and social sweepstakes, aimed at engaging younger audiences and enhancing brand visibility.
- Market Demand: Research indicates that one in four Super Bowl viewers experience occasional heartburn while enjoying their favorite foods, with 75% unprepared for relief, highlighting a significant market need for quick and effective heartburn solutions.
- Product Innovation: The Burn Ball football is not only a limited-edition item but also specifically designed to pass TUMS, providing consumers with a fast-acting heartburn relief solution on game day, thereby enhancing the brand's competitive edge in the market.
- Marketing Strategy: By integrating sports and entertainment elements, TUMS's innovative product is expected to attract more young consumers, boost brand loyalty, and drive sales growth, particularly during the critical Super Bowl marketing window.
See More

- Limited Edition Product Launch: TUMS introduces the first-ever Burn Ball football, specifically designed for fast heartburn relief, which is expected to attract a large consumer base and enhance brand visibility.
- Social Campaign Promotion: Partnering with YouTube star Eric Decker, TUMS launches the #PassTheTUMS campaign, encouraging users to share creative videos, which is anticipated to boost brand engagement and attract younger consumers.
- Prize Incentive Mechanism: The campaign features a $5,000 grand prize and 50 $50 UberEats gift cards, aimed at increasing participation and further driving brand loyalty through reward mechanisms.
- Market Research Support: A survey by Talker Research indicates that one in four viewers experiences heartburn while watching the Super Bowl, highlighting the market demand and potential growth opportunities for TUMS products.
See More
- Brand Trust Recognition: Haleon has been honored in Fast Company's 2025 Brands That Matter list in the Family of Brands category, highlighting its exceptional performance in consumer trust and brand impact, thereby reinforcing its leadership position in the global consumer health market.
- Cultural Relevance: This award signifies Haleon's success in establishing deep connections with consumers through science-backed products and transparent communication, reflecting its sense of mission and responsibility in promoting everyday health.
- Diverse Brand Portfolio: Haleon's portfolio includes globally recognized brands such as Sensodyne, Centrum, and Advil, showcasing its ability to meet consumer needs and enrich cultural conversations around health, enhancing emotional resonance with consumers.
- Strategic Mission: Haleon is committed to empowering consumers' health decision-making through cross-brand collaboration and innovation, further advancing its mission to put better everyday health in more hands, demonstrating its strategic significance in the global market.
See More
- Brand Impact: Haleon has been recognized in Fast Company’s 2025 Brands That Matter list in the Family of Brands category, highlighting its ability to create cultural moments across multiple brands, thereby reinforcing its leadership position in the global consumer health market.
- Consumer Trust: The company's portfolio includes globally recognized brands like Sensodyne, Centrum, and Advil, which are backed by science and committed to transparent communication and meaningful health initiatives, enhancing consumer trust and brand loyalty.
- Innovation-Driven: Through insights-driven innovation and consumer education, Haleon not only meets consumer needs but also enriches cultural conversations surrounding health and self-care, further boosting its competitive edge in the market.
- Global Mission: Haleon’s brands unite under a shared mission to deliver better everyday health to more people, reflecting its strong commitment to consumer wellbeing and laying a foundation for future growth.
See More
ETF Performance Overview: The GMO International Quality ETF saw significant trading volume on Tuesday, with Haleon and Novo Nordisk experiencing slight declines of 0.6% and 0.7%, respectively.
Top Performer: Unilever stood out as the best-performing component of the ETF, rising by approximately 3.3% during the session.
Underperformer: Diageo lagged behind other components, trading lower by about 2.6%.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
See More






